AMLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amylyx Pharmaceuticals Inc (AMLX) is not a strong buy for a beginner investor with a long-term strategy at this time. While there are positive technical indicators and analyst ratings, the company's financial performance is weak, with significant revenue and income declines. Additionally, the lack of recent news or significant catalysts makes it less compelling as an immediate investment opportunity.
The technical indicators suggest a bullish trend. The MACD is positive and expanding, the RSI is neutral at 70.487, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 15.053), which could act as a barrier for further upward movement.
Analysts have raised price targets recently, reflecting optimism about the company's lead drug avexitide and its potential approval path. The SwingMax signal from 2026-02-10 shows a slight positive price change since then.
The company's financials are weak, with revenue and gross margin dropping to zero in Q3 2025, and net income declining significantly. There is no recent news or significant trading activity from hedge funds, insiders, or Congress members.
In Q3 2025, revenue dropped to $0 (-100% YoY), net income fell to -$34.39M (-52.7% YoY), and EPS dropped to -0.37 (-65.42% YoY). Gross margin also dropped to 0 (-100% YoY). These figures indicate poor financial health.
Analysts are optimistic, with recent price target increases to $19 and $28, and consistent Buy or Outperform ratings. This reflects confidence in the company's drug pipeline and potential future approvals.
